Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

MiRNA expession data in breast cancer and adjacent normal tissues

ABSTRACT: We select 3 pairs of tissue samples, including 3 breast tissues and 3 adjacent tissues, and then perform miRNA chip detection to find differential miRNAs. We used microarrays to identify differential expressed miRNAs in breast cancer and paired normal breast tissue

ORGANISM(S): synthetic construct Homo sapiens

PROVIDER: GSE143564 | GEO | 2020/01/16

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

miRNA expession data in breast cancer and adjacent normal tissues

Project description:miRNA expession data in breast cancer and adjacent normal tissues

| PRJNA600960 | ENA

Applied Biosystems Human TaqMan Low Density Array (TLDA) in HCC tumor and adjacent non-tumor tissues

Project description:MicroRNAs (miRNAs) are aberrant expressed in hepatocellular carcinoma (HCC) tissue and play a central role in diverse biological processes. We conducted a genome-wide miRNAs screening in 10 pairs of HCC tumor and adjacent non-tumor tissues to test the hypothesis that dysregulation of miRNAs in HCC tumor tissue are partially due to aberrant methylation in relevant miRNAs host genes. Taqman low density arrays were used to examine miRNA profiles in paired HCC tissues, and quantitative RT-PCR was used to validate candidate miRNAs for both discovery and validation sets.

2014-02-08 | GSE54751 | GEO

Applied Biosystems Human TaqMan Low Density Array (TLDA) in HCC tumor and adjacent non-tumor tissues

2014-02-08 | E-GEOD-54751 | biostudies-arrayexpress

Epigenome analysis of tumor adjacent normal tissue from breast cancer patients

Project description:Genome wide DNA methylation profiling of tumor adjacent normal tissue from patients with invasive breast cancer, as well as tissue from women undergoing reduction mammoplasty or prophylactic surgery. The Illumina Infinium 450k Human DNA methylation Beadchip was used to obtain DNA methylation profiles across approximately 485,577 CpGs in snap frozen breast tissue. Samples included 70 tumor-adjacent normal breast tissue with invasive disease, 8 tissues from breast prophylactic patients, and 18 tissues from breast reduction patients.

2015-04-15 | GSE67919 | GEO

Tumor and adjacent normal tissue

Project description:Proteome characterization of 5 breast tumors and adjacent normal tissue using HiRIEF nanoLC-MS/MS.

2019-02-04 | PXD011385 | JPOST Repository

miRNA profiling of GFAP+ cells isolated from GBM and adjacent non-tumor glial brain tissues

Project description:To identify miRNAs expression changes in human gliomas, we conducted a comprehensive microarray analysis to compare miRNA expression profiles in primary cells obtained from matched pairs of GBM and adjacent non-tumor brain tissues from 6 patients.

2013-03-01 | GSE44726 | GEO

MicroRNA expression profile of breast cancer patients with adjacent normal control group.

Project description:To discriminate miRNA expression differences between adjacent normal and tumor tissues of breast cancer. 101 breast tumor + 15 adjacent breast normal tissue samples.

2013-11-12 | E-GEOD-45666 | biostudies-arrayexpress

Epigenome analysis of tumor adjacent normal tissue from breast cancer patients

2015-04-15 | E-GEOD-67919 | biostudies-arrayexpress

RNA-Seq in four pairs of human gastric cancer and matched adjacent normal tissue specimens

Project description:Total RNA was extracted from human gastric cancer tissues (n=4) and matched adjacent normal tissues (n=4) . RNA samples were analyzed by RNA sequencing based on the manufacturer’s protocols. Briefly, Illumina HiSeq 4000 platform was used to sequence the RNA samples for the subsequent generation of raw data. R package was utilized to select lncRNAs with significantly differential expression based on fold change >2 or <1/2, p value <0.05 between human gastric cancer tissues and matched adjacent normal tissues, and the top 10 upregulated lncRNAs were selected for further study.

2022-10-12 | GSE172032 | GEO

Tumor Intrinsic Subtype is Reflected in Cancer-Adjacent Benign Tissue

Project description:Introduction: Overall survival of early-stage breast cancer (BC) patients is similar for those who undergo breast conserving therapy (BCT) and mastectomy, however, 10-15% of women undergoing BCT suffer ipsilateral breast tumor recurrence. The risk of recurrence may vary with age or breast cancer subtype. Understanding the gene expression of the cancer-adjacent tissue and/or stromal response to specific tumor subtypes is important for developing clinical strategies to reduce recurrence risk. Methods: We studied gene expression data in cancer-adjacent tissue from 158 BC patients. Complementary in vitro cocultures were used to study cell-cell communication between fibroblasts and specific breast cancer subtypes. Results: Our results suggest that intrinsic tumor subtypes are reflected in histologically normal cancer-adjacent tissue. Gene expression of cancer-adjacent tissues shows that triple negative (Claudin-low or Basal-like tumors) exhibit increased expression of genes involved in inflammation and immune response. While such changes could reflect distinct immune populations present in the microenvironment of different breast cancer subtypes, altered immune response gene expression was also observed in cocultures in the absence of immune cell infiltrates, emphasizing that these inflammatory mediators are secreted by breast-specific cells. In addition, while triple negative BCs are associated with upregulated immune response genes, Luminal breast cancers are more commonly associated with estrogen-response in adjacent tissues. Conclusions: Specific characteristics of BCs are reflected in the surrounding benign tissue. This commonality between tumor and surrounding tissue may underlie second primaries and local recurrences. Biomarkers derived from cancer-adjacent tissue may be helpful in defining personalized surgical strategies or in predicting recurrence risk.

2014-04-30 | GSE50939 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data